Biomimetic medical adhesives

01Overview and value chain

Markers: [EC: MDR 2017/745 | OECD: Biotech-health | Regulator: FDA (USA), EMA (European Union), NMPA (China)]

Biomimetic medical adhesives bond, seal or stop bleeding in wet, moving tissue environments where conventional sutures and staples are slow, traumatic or ineffective, drawing on biological adhesion mechanisms — such as the proteins mussels and oysters use to bond to wet rock — to work where synthetic glues typically fail. Tissium’s bioinspired polymer platform recently published first-in-human clinical results for its Coaptium Connect system, an atraumatic sutureless nerve-repair device, and the company secured EUR 60 million to support commercial and clinical activities and platform expansion, following an earlier EUR 30 million equity plus EUR 30 million debt raise. Cresilon’s biomimetic hemostatic gel technology, marketed as TraumaGel, showed promising results for treating penetrating traumatic brain injury in a study with the Walter Reed Army Institute of Research, received an Innovative Technology contract from Vizient, and was named to Fast Company’s Most Innovative Companies list for 2026. Brij Medical launched Brij-Seal, expanding its incision-management portfolio with an advanced wound sealant engineered for strength, flexibility and biocompatibility, alongside its BRIJJIT product line securing an ECAT government-procurement listing. In Germany, Adhesys Medical develops polyurethane-based surgical adhesive and sealant technology.

The key directions of biomimetic medical adhesives are:

1. Bioinspired sutureless tissue repair (Bioinspired Sutureless Repair): biomimetic polymer platforms replacing sutures for nerve and soft-tissue repair, validated in first-in-human clinical studies — Tissium’s Coaptium Connect.
2. Biomimetic hemostatic gel technology (Biomimetic Hemostatic Gel): rapid-acting hemostatic gels inspired by biological adhesion chemistry, validated for trauma and penetrating-injury bleeding control — Cresilon’s TraumaGel.
3. Advanced wound sealants (Advanced Wound Sealants): incision-management sealants engineered for strength, flexibility and biocompatibility as an adjunct or alternative to sutures — Brij Medical’s Brij-Seal.
4. Polyurethane-based surgical adhesives (Polyurethane Surgical Adhesives): synthetic polyurethane adhesive chemistry adapted for surgical tissue bonding — Adhesys Medical.

Sectoral value chain

[bioinspired adhesive chemistry design] ──> [preclinical/clinical validation] ──> [regulatory clearance (FDA/MDR)]
                                                    │
                                       (surgical/trauma deployment)
                                                    │
                                                    ▼
[label expansion to new indications] <─── [clinical outcome data generation] <─────┘

Value chain levels

Cross-cutting technologies of the sector:

• Biomimetic adhesion chemistry (Bioinspired Sutureless Repair): polymer chemistries that replicate the wet-surface bonding mechanisms biological organisms (mussels, oysters) use, enabling adhesion where conventional synthetic glues fail on moist tissue.
• Rapid hemostatic gelation (Biomimetic Hemostatic Gel): gel formulations that rapidly clot or seal a bleeding wound on contact, validated for trauma and penetrating-injury control.
• Engineered sealant mechanics (Advanced Wound Sealants): formulations balancing strength, flexibility and biocompatibility to function as a sutureless or suture-adjunct incision seal.

02US

The US hosts leading biomimetic adhesive and hemostatic gel companies, with real-world trauma and defense-research validation data.

Cresilon, Brij Medical, FDA

• Cresilon: its biomimetic hemostatic gel, marketed as TraumaGel, showed promising results for treating penetrating traumatic brain injury in a study with the Walter Reed Army Institute of Research, received an Innovative Technology contract from Vizient, and was named to Fast Company’s Most Innovative Companies list for 2026.
• Brij Medical: launched Brij-Seal, expanding its incision-management portfolio with an advanced wound sealant engineered for strength, flexibility and biocompatibility, alongside its BRIJJIT product line securing an ECAT government-procurement listing.
• FDA framework: biomimetic adhesives, sealants and hemostatic gels clear the FDA via 510(k) or PMA review as surgical devices, with each specific indication (nerve repair, hemorrhage control, incision sealing) requiring its own clinical-validation evidence.

03CN

No dedicated Chinese biomimetic medical adhesive company cleared source confirmation as of 2026; Chinese sources covering this period center on the broader tissue-sealant and medical-adhesive market rather than a specific biomimetic commercial originator.

market coverage, NMPA pathway

• Market coverage focus: Chinese industry reporting on tissue sealants and medical adhesives in this period addresses the broader product category rather than a dedicated biomimetic-adhesive platform company.
• NMPA pathway: any biomimetic surgical adhesive reaching Chinese clinical use would register with NMPA as a medical device, following a validation-heavy pathway given the surgical-use risk classification.

04EU

France and Germany anchor Europe’s biomimetic adhesive capacity, spanning a well-funded sutureless-repair platform and polyurethane-based surgical adhesive chemistry.

Tissium, Adhesys Medical, MDR

• Tissium (Paris, France): its bioinspired polymer platform recently published first-in-human clinical results for its Coaptium Connect atraumatic sutureless nerve-repair system, and secured EUR 60 million to support commercial and clinical activities and platform expansion, following an earlier EUR 30 million equity plus EUR 30 million debt raise.
• Adhesys Medical (Germany): develops polyurethane-based surgical adhesive and sealant technology for tissue bonding applications.
• MDR framework: biomimetic surgical adhesives sold in the EU require conformity assessment under the Medical Device Regulation (MDR 2017/745), with Tissium’s first-in-human data supporting its path through that framework.

05Leading companies and research institutes

06Tech stack and innovations

The stack applies biologically inspired adhesion and gelation chemistry to bond, seal or stop bleeding in wet tissue environments where conventional sutures, staples and synthetic glues typically underperform.

1. Bioinspired sutureless repair polymers (Bioinspired Sutureless Repair):
   • Tissium’s biomimetic polymer platform, validated in first-in-human clinical results for its Coaptium Connect system, replaces sutures for atraumatic nerve repair.
2. Rapid biomimetic hemostatic gelation (Biomimetic Hemostatic Gel):
   • Cresilon’s TraumaGel gel technology rapidly controls bleeding on contact, validated in trauma and penetrating traumatic brain injury studies conducted with the Walter Reed Army Institute of Research.
3. Engineered wound-sealant mechanics (Advanced Wound Sealants):
   • Brij Medical’s Brij-Seal is engineered for a balance of strength, flexibility and biocompatibility, expanding the company’s incision-management portfolio alongside its BRIJJIT product line.
4. Polyurethane surgical adhesive chemistry (Polyurethane Surgical Adhesives):
   • Adhesys Medical adapts polyurethane adhesive chemistry for surgical tissue-bonding applications.

07Value chains and production pipelines

Industrial pipeline of a biomimetic medical adhesive (FDA 510(k)/PMA / EU MDR 2017/745)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Adhesive chemistry     │ ───> │ 2. Preclinical/clinical   │
│    design                   │      │    validation                │
└───────────────────────────┘      └───────────────────────────┘
                                                   │
                                                   ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Surgical/trauma        │ <─── │ 3. Regulatory clearance  │
│    deployment                │      │                           │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Clinical outcome data  │ ───> │ 6. Label expansion        │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Adhesive chemistry design

A polymer or gel chemistry is engineered to replicate a biological adhesion mechanism — such as mussel- or oyster-inspired wet-surface bonding — for a specific surgical or trauma bonding, sealing or hemostatic function.

Stage 2: Preclinical and clinical validation

The formulation is tested for adhesion strength, biocompatibility and functional performance (nerve repair, hemorrhage control, incision sealing) in animal studies and, as Tissium and Cresilon have both achieved, human clinical studies.

Stage 3: Regulatory clearance

The device clears FDA 510(k)/PMA review or EU MDR conformity assessment for its specific surgical indication, with Tissium’s first-in-human nerve-repair data and Cresilon’s trauma studies both supporting this stage.

Stage 4: Surgical and trauma deployment

The cleared adhesive, sealant or hemostatic gel is used in the operating room (Tissium, Adhesys Medical) or trauma/field setting (Cresilon), replacing or supplementing sutures and staples where they underperform.

Stage 5: Clinical outcome data generation

Real-world and study data on bleeding control, healing and complication rates are collected, the evidence base behind Cresilon’s Walter Reed-validated trauma results and Vizient contract.

Stage 6: Label expansion

Outcome evidence supports expanding the approved indication to new surgical or trauma use cases, the pattern behind Brij Medical’s expansion from its initial BRIJJIT product into the broader Brij-Seal incision-management line.